FGFR3 inhibitors have shown anti-tumor cell proliferation and pro-apoptotic effects on bladder cancer cells carrying FGFR3 gene mutations, indicating that the status of FGFR3 gene mutations can predict patients’ response to targeted therapy. This evidence concerns the gene FGFR3 and urinary bladder cancer.